The PRAC’s November meeting (27th – 30th) saw a host of topics discussed, including:
- The commencement of a review of Esmya (ulipristal acetate), a medicine used to treat uterine fibroids.
- The recommendation that modified- or prolonged-release paracetamol-containing medicines should be suspended from the market.
- The PRAC also adopted a revision to its strategy to measure the impact of pharmacovigilance activities (originally launched in 2016).
The full meeting highlights are available on the EMA website here